New drug IBI3032 tested for safety in small human study

NCT ID NCT07134127

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety and how the body handles a single dose of IBI3032 in 40 healthy adults. Participants were randomly assigned to receive either IBI3032 or a placebo, and some groups also looked at the effect of food on the drug. The study is complete and focused on side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IBI3032

What could go wrong

This is a very early Phase 1 study in only 40 healthy people, so it cannot show whether IBI3032 works for any disease. The main goal is safety, not effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Frist Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China